Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
United States Subgroup of the Denali Trial: A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension

February 24, 2026

View Press Release Corporate presentation Contact us
Previous